



SPIMACO Forges Strategic Alliance with Recbio for Recombinant HPV-9 Vaccine

January 23, 2024 - Saudi Pharmaceutical Industries and Medical Appliances Corporation ("SPIMACO"), a National Champion in the Saudi Pharma industry, and Jiangsu Recbio Technology Co., Ltd. ("Recbio"), an innovative Chinese vaccine company, have established a strategic alliance for the licensing, supply and technology transfer of Recombinant Human Papillomavirus (HPV) 9-valent vaccines.

Under the agreement, SPIMACO will gain exclusive rights to conduct clinical studies and, subject to regulatory approval, will take charge of the registration, distribution, and commercialization of the HPV-9 Vaccine in Saudi Arabia and the broader MENA region. This will involve the import of finished and ready-to-fill bulk forms of the vaccine, followed by local filling and packaging processes overseen by SPIMACO.

The partnership also includes a technology transfer initiative, leveraging Recbio's expertise, knowledge, and experience to facilitate local manufacturing of the HPV-9 vaccine. This strategic move aims to increase accessibility and affordability of the vaccines within the region, ultimately ensuring safe and timely access for populations across the Kingdom and the MENA region.

Jerome Cabannes, CEO of SPIMACO, stated: "This collaboration with Recbio strengthens SPIMACO's dedication to advancing Health Transformation in Saudi Arabia, marking a significant milestone in the Kingdom's pursuit of becoming a pivotal hub for pharmaceutical manufacturing. SPIMACO remains committed to delivering innovative, high-quality, and affordable vaccines, aiming to enhance preventive care and overall population health in the region."

Press Release



Dr. Liu Yong, Founder of Recbio, added: "We are thrilled to forge this alliance with SPIMACO, a true champion in the region. This collaboration represents a powerful synergy between our expertise and SPIMACO's established presence in the Middle East. With Recbio's 9-valent HPV vaccine nearing commercialization, this is the perfect moment to join forces and ensure its swift and efficient market entry across 15 countries, benefiting populations throughout the MENA region."

HPV 9-valent vaccines are widely regarded as the most effective vaccines against HPV infections and can prevent approximately 90% of cervical cancers. Under the endorsement of the Saudi Ministry of Health, the HPV vaccine is included in Saudi Arabia's national immunization schedule.

- ENDS -



NOTES TO EDITORS

About Recbio

Founded in 2012, Jiangsu Recbio Technology Co., Ltd (Recbio, HKEK:2179) is an innovative vaccine company driven by self-developed technologies. The Company is dedicated to the R&D, production, and commercialization of innovative vaccines, leveraging its core technology platforms (novel adjuvant, protein engineering, immunological evaluation). Staying true to the mission of “Protect human health with best-in-class vaccines”, Recbio has established high-value pipelines consisting of several blockbuster vaccines with proprietary rights to satisfy the huge unmet demands in the markets of high-burden diseases.

With robust R&D capacity, the Company has developed high-value innovative vaccine portfolios covering cervical cancer, shingles, COVID-19, Respiratory Syncytial Virus (RSV), Cytomegalovirus (CMV), Herpes Simplex Virus (HSV), tuberculosis (TB) and other high-burden diseases.

About SPIMACO

Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO, Tadawul: 2070), headquartered in Riyadh, Saudi Arabia, is a leading pharmaceutical manufacturer extending its operations to 16 countries. Renowned for its production of high-quality generics, SPIMACO serves a diverse range of over 60 therapeutic categories, establishing itself as a strategic partner for major global and regional pharmaceutical companies.

Operating out of two state-of-the-art production facilities in Qassim and Dammam, the company boasts 7 production lines with a combined capacity exceeding 1,750 million units annually, and offers a wide range of pharmaceutical products including Oral Solids & Liquids, Creams, Aseptic Injectables, Suppositories, and Active Pharmaceutical Ingredients (APIs). With a dedicated workforce of over 1,200 employees, SPIMACO is steadfast in its commitment to sustainable growth and innovation.

Press Release



CONTACTS

Recbio – Investor Contact

ir@recbio.cn

SPIMACO - Institutional Investor Contact

Ghida Obeid

Head of Investor Relations

ghida.obeid@spimaco.sa